Skip to content

MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER

MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07458022
Enrollment
50
Registered
2026-03-09
Start date
2025-12-01
Completion date
2026-04-01
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Diorder

Keywords

Major Depressive, selective serotonin, magnesium, combination therapy symptoms

Brief summary

Role of Magnesium in Depressive Disorder

Detailed description

Because of the significant role that magnesium serves in mood regulation, the goal of this study is to evaluate the impact of starting the therapy of major depressive disorder with a combination of SSRI and Mg, as well as SSRI alone.

Interventions

DRUGUse of magnesium with SSRI

Impact of combination of SSRI and Magnesium in Major Depressive Disorder

DRUGSSRI

Only SSRI will be given

Sponsors

University of Child Health Sciences and Children's Hospital, Lahore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All patients of above 18 years diagnosed with DSM who had MDD and receiving SSRI alone and SSRI plus magnesium.

Exclusion criteria

Individuals who recently underwent treatment with electroconvulsive therapy, have a history of epilepsy or other severe neurological problems, have experienced a head injury, are cognitively impaired, and have comorbid conditions such as liver, renal, cardiovascular, neurological, or endocrine, or respiratory problems, or are pregnant or nursing mothers

Design outcomes

Primary

MeasureTime frameDescription
Change in severity of depressive symptomsFour WeeksChange in severity of depressive symptoms, measured by the difference in mean scores on the Beck Depression Inventory-II (BDI-II) from baseline to 4 weeks post-intervention

Countries

Pakistan

Contacts

STUDY_CHAIRAtif Najum, MBBS, FCPS

CMH Multan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026